The estimated Net Worth of Thomas Englese is at least $27.1 Thousand dollars as of 8 March 2023. Mr Englese owns over 937 units of Aziyo Biologics stock worth over $27,127 and over the last 4 years he sold AZYO stock worth over $0.
Sign up
Mr Englese AZYO stock SEC Form 4 insiders trading
Mr has made over 4 trades of the Aziyo Biologics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 937 units of AZYO stock worth $1,396 on 8 March 2023.
The largest trade he's ever made was exercising 15,390 units of Aziyo Biologics stock on 8 September 2022 worth over $22,931. On average, Mr trades about 4,369 units every 90 days since 2020. As of 8 March 2023 he still owns at least 18,206 units of Aziyo Biologics stock.
You can see the complete history of Mr Englese stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Thomas Englese biography
Thomas Englese is the Chief Commercial Officer at Aziyo Biologics.
How old is Mr Englese?
Mr Englese is 47, he's been the Chief Commercial Officer of Aziyo Biologics since . There are 6 older and no younger executives at Aziyo Biologics. The oldest executive at Aziyo Biologics, Inc. is Dr. Jerome Riebman FACC, M.A., M.D., 67, who is the Chief Medical Officer.
What's Mr Englese's mailing address?
Thomas's mailing address filed with the SEC is C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING, MD, 20904.
Insiders trading at Aziyo Biologics
Over the last 4 years, insiders at Aziyo Biologics have traded over $0 worth of Aziyo Biologics stock and bought 1,874,715 units worth $13,645,959 . The most active insiders traders include Capital, L.P.Highcape Partn..., Capital, Lp Birchview Fund ..., and C Randal Mills. On average, Aziyo Biologics executives and independent directors trade stock every 41 days with the average trade being worth of $124,230. The most recent stock trade was executed by C Randal Mills on 21 June 2023, trading 22,474 units of AZYO stock currently worth $33,486.
What does Aziyo Biologics do?
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
What does Aziyo Biologics's logo look like?
Complete history of Mr Englese stock trades at Aziyo Biologics
Aziyo Biologics executives and stock owners
Aziyo Biologics executives and other stock owners filed with the SEC include:
-
Ronald K. Lloyd,
CEO, Pres & Director -
Dr. Jerome Riebman FACC, M.A., M.D.,
Chief Medical Officer -
Dr. Darryl Roberts Ph.D.,
Exec. VP of Operations & Product Devel. -
Peter G. Edwards Esq.,
Gen. Counsel -
Courtney Guyer,
VP of Marketing -
Matthew B. Ferguson,
Chief Financial Officer -
Jeffry D. Hamet,
VP of Fin. -
Kevin L. Rakin M.B.A, M.S.,
Exec. Chairman -
Thomas Englese,
Chief Commercial Officer -
Maybelle Jordan,
-
Brigid Makes,
-
Partners Gp Ii, Llc High Ca...,
-
Jerome Riebman,
CHIEF MEDICAL OFFICER -
Matthew Ferguson,
CHIEF FINANCIAL OFFICER -
Ronald K. Lloyd,
PRESIDENT AND CEO -
Thomas Englese,
CHIEF COMMERCIAL OFFICER -
Darryl Roberts,
EVP, OPERATIONS & PRODUCT DEV. -
Capital, L.P.Highcape Partn...,
-
Peter G Edwards,
GENERAL COUNSEL -
David Colpman,
-
Michelle Le Roux Williams,
CHIEF SCIENTIFIC OFFICER -
Capital, Lp Birchview Fund ...,
-
C Randal Mills,
PRESIDENT AND CEO